MedTrace Logo

Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

NCT02902484 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-06-03

Study results available
· View outcomes & findings →

Summary

The study will perform a clinical study evaluating the safety and tolerability of nintedanib when combined with standard chemotherapy (Gemcitabine + nab-Paclitaxel) for metastatic pancreatic cancer. It will utilize advanced imaging correlates including dynamic contrast enhanced Magnetic Resonance Imaging (DCE-MRI) which correlates with tumor grade and microvessel density.

Conditions

  • Cancer of Pancreas

Interventions

DRUG

Nintedanib

Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • The University of Texas Health Science Center at San Antonio

    collaborator OTHER

  • South Plains Oncology Consortium

    collaborator NETWORK

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Salwan Al Mutar, MD · UT Southwestern

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-07
Primary Completion
2021-10-26
Completion
2021-10-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02902484 on ClinicalTrials.gov